Form 4 for RPID RAPID MICRO BIOSYSTEMS, INC.
Accepted 2021-07-20 00:00:00 ET · period of report 2021-07-19 · accession 0001104659-21-094111 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2021-07-20 | 2021-07-19 | RPID | Kollender Richard S | Dir | C - Cnv Deriv | — | +1.32M | 1.37M | +2,263% | — |
| DMI | 2021-07-20 | 2021-07-19 | RPID | Kollender Richard S | Dir | C - Cnv Deriv | — | -7.01M | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2021-07-19 | C | A | 1,315,084 | — | 1,373,193 | I Held by Quaker Bioventures II, L.P. | — | — | (F1) The Series A1 Preferred Stock, the Series B1 Preferred Stock and the Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. (F2) These shares are held directly by Quaker Bioventures II, L.P. The Reporting Person is a managing director of Quaker Bioventures Capital II, L.P., the parent of Quaker Bioventures II, L.P. and may be deemed to beneficially hold the shares. |
| 2 | Derivative | Series B1 Warrant | 2021-07-19 | C | D | 64,516 | — | 0 | I Held by Quaker Bioventures II, L.P. | $0.01 · — to 2027-12-06 | 64,516 Series B1 Preferred Stock | (F3) The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants. (F2) These shares are held directly by Quaker Bioventures II, L.P. The Reporting Person is a managing director of Quaker Bioventures Capital II, L.P., the parent of Quaker Bioventures II, L.P. and may be deemed to beneficially hold the shares. (F4) Immediately exercisable. |
| 3 | Derivative | Common Stock Warrant | 2021-07-19 | C | A | 12,903 | — | 12,903 | I Held by Quaker Bioventures II, L.P. | $0.05 · — to 2028-01-17 | 12,903 Class A Common Stock | (F3) The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants. (F2) These shares are held directly by Quaker Bioventures II, L.P. The Reporting Person is a managing director of Quaker Bioventures Capital II, L.P., the parent of Quaker Bioventures II, L.P. and may be deemed to beneficially hold the shares. (F4) Immediately exercisable. |
| 4 | Derivative | Common Stock Warrant | 2021-07-19 | C | A | 82,010 | — | 82,010 | I Held by Quaker Bioventures II, L.P. | $0.05 · — to 2027-07-24 | 82,010 Class A Common Stock | (F3) The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants. (F2) These shares are held directly by Quaker Bioventures II, L.P. The Reporting Person is a managing director of Quaker Bioventures Capital II, L.P., the parent of Quaker Bioventures II, L.P. and may be deemed to beneficially hold the shares. (F4) Immediately exercisable. |
| 5 | Derivative | Series A1 Warrant | 2021-07-19 | C | D | 410,051 | — | 0 | I Held by Quaker Bioventures II, L.P. | $0.01 · — to 2027-07-24 | 410,051 Series A1 Preferred Stock | (F3) The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants. (F2) These shares are held directly by Quaker Bioventures II, L.P. The Reporting Person is a managing director of Quaker Bioventures Capital II, L.P., the parent of Quaker Bioventures II, L.P. and may be deemed to beneficially hold the shares. |
| 6 | Derivative | Series C1 Preferred Stock | 2021-07-19 | C | D | 820,729 | — | 0 | I Held by Quaker Bioventures II, L.P. | — · — to — | 164,145 Class A Common Stock | (F1) The Series A1 Preferred Stock, the Series B1 Preferred Stock and the Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. (F2) These shares are held directly by Quaker Bioventures II, L.P. The Reporting Person is a managing director of Quaker Bioventures Capital II, L.P., the parent of Quaker Bioventures II, L.P. and may be deemed to beneficially hold the shares. |
| 7 | Derivative | Series B1 Preferred Stock | 2021-07-19 | C | D | 1,130,906 | — | 0 | I Held by Quaker Bioventures II, L.P. | — · — to — | 226,180 Class A Common Stock | (F1) The Series A1 Preferred Stock, the Series B1 Preferred Stock and the Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. (F2) These shares are held directly by Quaker Bioventures II, L.P. The Reporting Person is a managing director of Quaker Bioventures Capital II, L.P., the parent of Quaker Bioventures II, L.P. and may be deemed to beneficially hold the shares. |
| 8 | Derivative | Common Stock Warrant | 2021-07-19 | C | A | 12,903 | — | 12,903 | I Held by Quaker Bioventures II, L.P. | $0.05 · — to 2027-12-06 | 12,903 Class A Common Stock | (F3) The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants. (F2) These shares are held directly by Quaker Bioventures II, L.P. The Reporting Person is a managing director of Quaker Bioventures Capital II, L.P., the parent of Quaker Bioventures II, L.P. and may be deemed to beneficially hold the shares. (F4) Immediately exercisable. |
| 9 | Derivative | Series A1 Preferred Stock | 2021-07-19 | C | D | 4,623,796 | — | 0 | I Held by Quaker Bioventures II, L.P. | — · — to — | 924,759 Class A Common Stock | (F1) The Series A1 Preferred Stock, the Series B1 Preferred Stock and the Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. (F2) These shares are held directly by Quaker Bioventures II, L.P. The Reporting Person is a managing director of Quaker Bioventures Capital II, L.P., the parent of Quaker Bioventures II, L.P. and may be deemed to beneficially hold the shares. |
| 10 | Derivative | Series B1 Warrant | 2021-07-19 | C | D | 64,516 | — | 0 | I Held by Quaker Bioventures II, L.P. | $0.01 · — to 2028-01-17 | 64,516 Series B1 Preferred Stock | (F3) The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants. (F2) These shares are held directly by Quaker Bioventures II, L.P. The Reporting Person is a managing director of Quaker Bioventures Capital II, L.P., the parent of Quaker Bioventures II, L.P. and may be deemed to beneficially hold the shares. (F4) Immediately exercisable. |